Suraksha Diagnostic IPO sees weak response, with 37% subscription; analysts advise avoiding due to high valuation and limited market presence.
We use cookies to ensure you get the best experience on our website. Cookies also help us deliver personalized advertisements through Google Ads.
Do you consent to the use of these cookies?